Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas

PURPOSE: Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non–voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models. We conducted a phase IB study combining CTO with t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Omuro, Antonio, Beal, Kathryn, McNeill, Katharine, Young, Robert J., Thomas, Alissa, Lin, Xuling, Terziev, Robert, Kaley, Thomas J., DeAngelis, Lisa M., Daras, Mariza, Gavrilovic, Igor T., Mellinghoff, Ingo, Diamond, Eli L., McKeown, Andrew, Manne, Malbora, Caterfino, Andrew, Patel, Krishna, Bavisotto, Linda, Gorman, Greg, Lamson, Michael, Gutin, Philip, Tabar, Viviane, Chakravarty, Debyani, Chan, Timothy A., Brennan, Cameron W., Garrett-Mayer, Elizabeth, Karmali, Rashida A., Pentsova, Elena
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2018
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5993168/
https://ncbi.nlm.nih.gov/pubmed/29683790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.9992
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak